Pseudo-epileptic seizures in children are not associated with enhanced plasma level of allopregnanolone.
Journal Title: Pharmacological Reports - Year 2007, Vol 59, Issue 6
Abstract
Among neurosteroids, allopregnanolone is the most potent endogenous positive modulator of GABA(A) receptors, and disturbances in its release may play a role in pathomechanism of some neurological and psychiatric disorders. In contrast to a large body of evidence on allopregnanolone involvement in pathogenesis of epilepsy, no data are available on its role in pseudoseizures. Therefore, the aim of the present study was to find out whether pseudoseizures are associated with changes in plasma allopregnanolone level in pediatric patients. This study was carried out on 45 children with video EEG-diagnosed pseudoseizures, divided into three groups according to results of placebo test i.e: (I) children with pseudoseizures attacks without antiepileptic drug treatment; (II) children with pseudoseizures attacks and treated with antiepileptic drugs; (III) children without pseudoseizures attacks and no treatment. Allopregnanolone level was estimated by radioimmunoassay in blood samples collected before and after provoking pseudoseizures by placebo. No significant changes have been found in allopregnanolone level between all experimental groups. This suggests that in contrast to epileptic seizures, during pseudoseizures no compensatory increase in the endogenous antiepileptic and anxiolytic neurosteroid release occurs. The low level of allopregnanolone may have a detrimental effect on GABAergic inhibitory system in the brain aggravating stress response and promoting pseudoseizure occurrence. On the other hand, the clinical value of allopregnanolone plasma level as a biomarker distinguishing between epileptic and pseudoseizures remains questionable due to its high inter-individual differences.
Authors and Affiliations
Marek Kaciński, Monika Leśkiewicz, Lucylla Jaworska-Feil, Anna Zając, Alicja Kubik, Bogusława Budziszewska, Władysław Lasoń
Keywords
Related Articles
- EP ID EP149683
- DOI -
- Views 78
- Downloads 0
Monocyte suppressing action of fenofibrate.
Since atherosclerosis has been proven to be an inflammatory disease, itis obvious that the proper treatment for dyslipidemia should not only correct lipid parameters but alsoinhibit inflammation. Monocytes and monocyte-d...
Effects of GABA(B) receptor ligands in animal tests of depression and anxiety.
Preclinical evidence strongly implicates GABA(B) receptors in the pathophysiology of several psychiatric disorders including anxiety and depression. In the present study, we investigated the effects of the selective GABA...
Partial agonist efficacy of EMD386088, a 5-HT6 receptor ligand, in functional in vitro assays.
Over recent years, the 5-hydroxytryptamine6 (5-HT6) receptor has emerged as a promising molecular target which interacts with several central nervous system acting drugs. In animal models, both agonists and antagonists o...
Effects of sildenafil on pentylenetetrazol-induced convulsions in mice and amygdala-kindled seizures in rats.
Sildenafil is the first marketed phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction and recently, for pulmonary hypertension. While the treatment was found to be highly effective, several adverse eff...
Synergistic interaction of pregabalin with the synthetic cannabinoid WIN 55,212-2 mesylate in the hot-plate test in mice: an isobolographic analysis.
Background: The aim of the study was to determine the type of interaction between pregabalin (a 3(rd)-generation antiepileptic drug) and WIN 55,212-2 mesylate (WIN - a highly potent non-selective cannabinoid CB1 and CB2...